Sandra Buratta Selected Research

Lipids

3/2024	Metabolic Profiling as an Approach to Differentiate T-Cell Acute Lymphoblastic Leukemia Cell Lines Belonging to the Same Genetic Subgroup.
1/2023	Lipid Biomarkers in Liquid Biopsies: Novel Opportunities for Cancer Diagnosis.
1/2022	Lipidic Profile Changes in Exosomes and Microvesicles Derived From Plasma of Monoclonal Antibody-Treated Psoriatic Patients.
12/2020	Lipidomic analysis of cancer cells cultivated at acidic pH reveals phospholipid fatty acids remodelling associated with transcriptional reprogramming.
4/2020	The n-10 Fatty Acids Family in the Lipidome of Human Prostatic Adenocarcinoma Cell Membranes and Extracellular Vesicles.
3/2019	Curcumin Analogue C1 Promotes Hex and Gal Recruitment to the Plasma Membrane via mTORC1-Independent TFEB Activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sandra Buratta Research Topics

Disease

5	Neoplasms (Cancer) 03/2024 - 03/2013
4	Neurodegenerative Diseases (Neurodegenerative Disease) 04/2020 - 03/2013
2	Parkinson Disease (Parkinson's Disease) 04/2020 - 07/2019
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 03/2024
1	Hemolysis 01/2023
1	Anemia 01/2023
1	Sickle Cell Anemia (Hemoglobin S Disease) 01/2023
1	COVID-19 01/2023
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022
1	Drug-Induced Abnormalities (Abnormalities, Drug Induced) 11/2021
1	Inflammation (Inflammations) 01/2021
1	Fibrosis (Cirrhosis) 01/2021
1	Breast Neoplasms (Breast Cancer) 12/2020
1	Melanoma (Melanoma, Malignant) 12/2020
1	Parkinsonian Disorders (Parkinsonism) 04/2020
1	Adenocarcinoma 04/2020
1	Autoimmune Diseases (Autoimmune Disease) 08/2019
1	Neuroblastoma 03/2019
1	Pain (Aches) 10/2018
1	Necrosis 03/2017
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/2011
1	Hypoxia (Hypoxemia) 05/2004

Drug/Important Bio-Agent (IBA)

6	LipidsIBA 03/2024 - 03/2019
3	Biomarkers (Surrogate Marker)IBA 03/2024 - 03/2013
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2019
2	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022 - 12/2020
2	Fatty Acids (Saturated Fatty Acids)IBA 12/2020 - 04/2020
2	RotenoneIBA 04/2020 - 07/2019
1	Hemoglobins (Hemoglobin)IBA 01/2023
1	Oxygen (Dioxygen)IBA 01/2023
1	CytokinesIBA 01/2023
1	secukinumabIBA 01/2022
1	Adalimumab (Humira)FDA Link 01/2022
1	Ustekinumab (CNTO 1275)FDA Link 01/2022
1	Amiodarone (Amiodarona)FDA LinkGeneric 11/2021
1	Nonesterified Fatty Acids (NEFA)IBA 01/2021
1	Membrane LipidsIBA 12/2020
1	Protein AggregatesIBA 04/2020
1	AntioxidantsIBA 04/2020
1	CurcuminIBA 04/2020
1	delta(6)-hexadecenoic acidIBA 04/2020
1	VaccinesIBA 08/2019
1	NeurotoxinsIBA 07/2019
1	GlycosphingolipidsIBA 03/2019
1	Glycoside Hydrolases (Endoglycosidases)IBA 03/2019
1	Local AnestheticsIBA 10/2018
1	Lidocaine (Xylocaine)FDA LinkGeneric 10/2018
1	Xylazine (Xylazin)IBA 03/2017
1	Dexmedetomidine FDA Link 03/2017
1	PhosphatidylserinesIBA 07/2011
1	ChromiumIBA 07/2011
1	Glutamic Acid (Glutamate)FDA Link 05/2004